NDASUBCUTANEOUSSOLUTION
Approved
Oct 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
LASIX ONYU (furosemide) by Innovation Pharmaceuticals is 12. First approved in 2025.
Drug data last refreshed 3m ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LASIX ONYU (furosemide) is a subcutaneous loop diuretic solution approved October 2025 for heart failure management. It works by inhibiting sodium and chloride reabsorption in the proximal and distal tubules and loop of Henle, producing sustained diuresis lasting at least 8 hours. This subcutaneous formulation offers an alternative delivery route to traditional intravenous or oral furosemide in NYHA Class II-III heart failure patients.
Launch
Early-stage launch product with moderate competitive pressure (30/100) creates near-term commercial team expansion opportunities in field sales, reimbursement, and market access roles.
Mechanism of Action
12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory…
Worked on LASIX ONYU at Innovation Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.